Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α

Genes and Development

Volumn 28, Issue 23, 2014, Pages 2621-2635

  Baer, Romain ^a,b   Cintas, Célia ^a,b   Dufresne, Marlène ^a   Cassant Sourdy, Stéphanie ^a,b   Schönhuber, Nina ^c   Planque, Laetitia ^a,b   Lulka, Hubert ^a   Couderc, Bettina ^a   Bousquet, Corinne ^a,b   Garmy Susini, Barbara ^d   Vanhaesebroeck, Bart ^e   Pyronnet, Stéphane ^a,b   Saur, Dieter ^c,f   Guillermet Guibert, Julie ^a,b  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Equipe Labellisée Ligue Nationale Contre le Cancer 2018   (France)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSERM   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Genetic mouse models; Oncogenes; Pancreas; PI3K isoforms; Signaling; Transdifferentiation

Indexed keywords

KRAS2 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P21;

ANIMAL; CELL PROLIFERATION; CYTOLOGY; EPITHELIUM CELL; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL CELLS; GENE SILENCING; HUMANS; MICE; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84914125441     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.249409.114     Document Type: Article

References (48)

1. Al-Adsani A, Burke ZD, Eberhard D, Lawrence KL, Shen CN, Rustgi AK, Sakaue H, Farrant JM, Tosh D. 2010. Dexamethasone treatment induces the reprogramming of pancreatic acinar cells to hepatocytes and ductal cells. PLoS ONE 5: e13650.
2. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, et al. 2012. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22: 304-317.
3. Berenjeno IM, Guillermet-Guibert J, Pearce W, Gray A, Fleming S, Vanhaesebroeck B. 2012. Both p110a and p110b isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J 442: 151-159.
4. Berglund FM,Weerasinghe NR, Davidson L, Lim JC, Eickholt BJ, Leslie NR. 2013. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110a/PIK3CA but not by HER2 or mutant AKT1. Oncogene 32: 4417-4426.
5. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, et al. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399-405.
6. Carriere C, Young AL, Gunn JR, Longnecker DS, Korc M. 2009. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun 382: 561-565.
7. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. 2011. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71: 5020-5029.
8. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, Cruz- Monserrate Z, Wang H, Ji B, Logsdon CD. 2012. An NF-kB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122: 1519-1528.
9. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et al. 2013. Selective requirement of PI3K/PDK1 signaling for Kras oncogenedriven pancreatic cell plasticity and cancer. Cancer Cell 23: 406-420.
10. Fendrich V, Esni F, Garay MV, Feldmann G, Habbe N, Jensen JN, Dor Y, Stoffers D, Jensen J, Leach SD, et al. 2008. Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology 135: 621-631.
11. Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbacher M, Stamp G, Downward J. 2013. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153: 1050-1063.
12. Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ et al. 2011. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19: 441-455.
13. Graupera M, Guillermet-Guibert J, Foukas LC, Phng L-K, Cain RJ, Salpekar A, PearceW, Meek S, Millan J, Cutillas PR, et al. 2008. Angiogenesis selectively requires the p110a isoform of PI3K to control endothelial cell migration. Nature 453: 662- 669.
14. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M. 2007. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
15. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJH, Okkenhaug K, Vanhaesebroeck B. 2008. The p110b isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110g. Proc Natl Acad Sci 105: 8292-8297.
16. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. 2007. Binding of ras to phosphoinositide 3-kinase p110a is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
17. Heasman SJ, Ridley AJ. 2008. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 9: 690-701.
18. Hidalgo M. 2010. Pancreatic cancer. N Engl J Med 362: 1605- 1617.
19. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, Dry S, Wu H. 2010. PTEN loss accelerates KrasG12Dinduced pancreatic cancer development. Cancer Res 70: 7114-7124.
20. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
21. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
22. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, Rewcastle GW, Denny WA, Singh R, Dickson J, et al. 2011. A drug targeting only p110a can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 438: 53-62.
23. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y,Wolff RA, Abbruzzese JL. 2010. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10: 368.
24. Jensen JN, Cameron E, Garay MV, Starkey TW, Gianani R, Jensen J. 2005. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology 128: 728-741.
25. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, et al. 2008. Essential roles of PI(3)Kp110b in cell growth, metabolism and tumorigenesis. Nature 454: 776-779.
26. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801- 1806.
27. Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP 4th, Pan FC, Akiyama H, Wright CV, Jensen K, et al. 2012. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22: 737-750.
28. Kowluru A, Seavey SE, Li G, Sorenson RL, Weinhaus AJ, Nesher R, Rabaglia ME, Vadakekalam J, Metz SA. 1996. Glucoseand GTP-dependent stimulation of the carboxyl methylation of CDC42 in rodent and human pancreatic islets and pure b cells. Evidence for an essential role of GTP-binding proteins in nutrient-induced insulin secretion. J Clin Invest 98: 540- 555.
29. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Yoshimura A, Reindl W, Sipos B, Akira S, et al. 2011. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
30. Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ, Australian Pancreatic Cancer Genome Initiative, et al 2012. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci 109: 5934- 5941.
31. Means AL, Meszoely IM, Suzuki K, Miyamoto Y, Rustgi AK, Coffey RJ Jr, Wright CV, Stoffers DA, Leach SD. 2005. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132: 3767-3776.
32. Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, et al. 2014. Targeting mTOR dependency in pancreatic cancer. Gut 63: 1481-1491.
33. Morris JP 4th, Cano DA, Sekine S, Wang SC, Hebrok M. 2010. b-Catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest 120: 508-520.
34. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. 2012. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22: 318-330.
35. Rodon J, Dienstmann R, Serra V, Tabernero J. 2013. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10: 143-153.
36. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. 1997. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: 457-467.
37. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. 2003. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115.
38. Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ. 2014. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci 111: 6395-6400.
39. Stanger BZ, Stiles B, Lauwers GY, Bardeesy N, Mendoza M, Wang Y, Greenwood A, Cheng KH, McLaughlin M, Brown D, et al. 2005. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8: 185-195.
40. Strobel O, Dor Y, Alsina J, Stirman A, Lauwers G, Trainor A, Castillo CF, Warshaw AL, Thayer SP. 2007. In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 133: 1999-2009.
41. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. 2005. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204.
42. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. 2010. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11: 329-341.
43. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E et al. 2014. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 4: 334-347.
44. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, et al. 2009. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27: 193-198.
45. Yadav D, Lowenfels AB. 2013. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144: 1252-1261.
46. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, et al. 2004. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10: 2846-2850.
47. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y,WangWet al. 2011. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kB-cytokine network. Cancer Discov 1: 158-169.
48. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. 2007. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171: 263- 273.